2024
PD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY
Loeb S, Gross L, Cheng H, Rivera A, Keith S, Byrne N, Nolasco T, Giri V. PD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY. Journal Of Urology 2024, 211: e62. DOI: 10.1097/01.ju.0001009540.33579.43.01.Peer-Reviewed Original Research
2022
Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families
Leader A, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri V. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal Of Community Genetics 2022, 13: 547-556. PMID: 35869324, PMCID: PMC9681950, DOI: 10.1007/s12687-022-00603-1.Peer-Reviewed Original ResearchGenetic test resultsProstate cancerGenetic testingDiagnosis of PCaFamily membersClinical trial optionsGermline genetic testingPV/LPVRelevant family membersGenetic testing experiencesImmediate family membersPCa patientsCancer screeningPatientsTrial optionsPrecision therapyGenetic resultsGenetic counselorsTesting experienceThematic analysisCommunication barriersSemi-structured interviewsParticipantsTherapyTestingGuidelines on Germline Testing for Urologic Tumor Syndromes
Gomella P, Mark J, Giri V, Kelly W, Gomella L. Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus 2022, 8: 670-673. PMID: 35803854, DOI: 10.1016/j.euf.2022.06.010.Peer-Reviewed Original ResearchConceptsGermline testingCurrent guidelinesTumor syndromeTreatment of patientsScreening of patientsAvailability of testingDifferent organ systemsGenitourinary cancersGenitourinary tractUrologic cancersTreatment decisionsPatientsOrgan systemsGene mutationsCancerGenetic mutationsSyndromeFamily membersTreatmentGuidelinesMutationsTestingUse of geneticsTract
2021
Adopting Consensus Terms for Testing in Precision Medicine
Martin N, Tepper J, Giri V, Stinchcombe T, Cheng H, Javle M, Konnick E. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precision Oncology 2021, 5: 1563-1567. PMID: 34651094, PMCID: PMC8509918, DOI: 10.1200/po.21.00027.Peer-Reviewed Original ResearchConceptsGenetic testingTreatment decisionsOncology health care providersHealth care providersPrecision medicineLow socioeconomic statusPreferred termPatient advocacy groupsGermline testingTumor characteristicsOncology carePatient preferencesBiomarker testingPatient educationCancer riskCare providersPatient confusionSolid tumorsBlood cancersGermline mutationsGermline variantsAppropriate testingPatientsSocioeconomic statusGenomic testing
2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice 2020, 16: 811-819. PMID: 32986533, PMCID: PMC7735040, DOI: 10.1200/op.20.00431.Peer-Reviewed Original ResearchConceptsGermline genetic testingProstate cancerGenetic testingNumber of patientsCritical unmet needCurrent guidelinesTesting deliveryPatientsUnmet needPrecision oncologyGenomic testingGenetic counselingGenetics providersGenetic servicesClinical workflowCancerOncologyLimited accessWorking GroupGuidelinesStandardized systemProvidersTestingClinic
2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN, Group P. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer 2019, 17: 275-282.e1. PMID: 31171481, PMCID: PMC6662206, DOI: 10.1016/j.clgc.2019.04.013.Peer-Reviewed Original ResearchConceptsProstate Cancer Clinical Trials ConsortiumGermline genetic testingClinical Trials ConsortiumGenetic testingPCa patientsAdvanced prostate cancer patientsAdvanced prostate cancerMetastatic PCa patientsClinical trial eligibilityProstate cancer patientsPan-cancer panelCancer gene panelTrial eligibilityChoice of assayLocal diseaseCancer CenterAcademic oncologistsCancer patientsProstate cancerCancer treatment facilitiesPatientsBusy clinicPrecision therapyPersonalized treatmentWorking Group
2017
Insurance status and patterns of late diagnosis and cancer treatment: A population-based study.
Lu-Yao G, He J, Giri V, Klassen A. Insurance status and patterns of late diagnosis and cancer treatment: A population-based study. Journal Of Clinical Oncology 2017, 35: e16553-e16553. DOI: 10.1200/jco.2017.35.15_suppl.e16553.Peer-Reviewed Original ResearchNon-Medicaid insurancePopulation-based studyLate diagnosisUninsured patientsLocalized cancerInsurance statusRadical prostatectomyDiagnosis periodEnd Results (SEER) databaseLocalized prostate cancerMarital statusProstate cancer patientsProstate cancer diagnosisLogistic regression modelsResults databaseRegional diseaseCancer patientsInsurance typeRelative riskMedicaid patientsProstate cancerPatientsAge 65Veterans AffairsPrivate insurancePrevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts
Truong H, Hegarty S, Gomella L, Kelly W, Trabulsi E, Lallas C, Giri V. Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts. Journal Of Genetic Counseling 2017, 26: 548-555. PMID: 28101821, DOI: 10.1007/s10897-016-0020-4.Peer-Reviewed Original ResearchConceptsRenal cell cancerReferral criteriaCell cancerReferral guidelinesDiagnosis of RCCConsensus criteriaInstitutional cancer registryCharacteristics of patientsReferral of patientsGenetic counselingChi-square testRate of whitesCross-sectional analysisCancer risk managementHereditary renal cell cancerSEER cohortWhite patientsBlack patientsInstitutional cohortRCC syndromesCancer RegistryPatient cohortKidney cancerAmerican CollegePatients
2016
Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
Myers R, Leader A, Censits J, Trabulsi E, Keith S, Petrich A, Quinn A, Den R, Hurwitz M, Lallas C, Hegarty S, Dicker A, Zeigler-Johnson C, Giri V, Ayaz H, Gomella L. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. Journal Of Cancer Education 2016, 33: 180-185. PMID: 27418065, DOI: 10.1007/s13187-016-1073-7.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerActive surveillanceProstate cancerDecision support interventionsActive treatmentDecisional conflictClinic visitsTreatment choiceClinician supportTreatment knowledgePatient choiceSupport interventionsBaseline surveyPilot studyCancerMenTreatmentParticipantsSurveillancePatientsFollowCliniciansSDMVisitsPD13-07 CHARACTERIZATION OF UPPER TRACT UROTHELIAL CARCINOMA IN PATIENTS WITH CLINICAL SUSPICION OF LYNCH SYNDROME
Truong H, Hegarty S, Hubosky S, Healy K, Hoffman-Censits J, Giri V. PD13-07 CHARACTERIZATION OF UPPER TRACT UROTHELIAL CARCINOMA IN PATIENTS WITH CLINICAL SUSPICION OF LYNCH SYNDROME. Journal Of Urology 2016, 195: e300. DOI: 10.1016/j.juro.2016.02.978.Peer-Reviewed Original ResearchHow I Do It: Genetic counseling and genetic testing for inherited prostate cancer.
Giri V, Gross L, Gomella L, Hyatt C. How I Do It: Genetic counseling and genetic testing for inherited prostate cancer. Canadian Journal Of Urology 2016, 23: 8247-53. PMID: 27085833.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancer patientsProstate cancerCancer patientsGenetic counselingProstate cancer risk assessmentGenetic testing guidelinesInherited prostate cancerHereditary cancer syndromesCancer risk assessmentProstate cancer predispositionFamily historyUrologic communityCancer syndromesCancerGenetic testingPatientsTesting guidelinesGenetic mutationsCounselingCancer predispositionUrologistsCurrent knowledgeSubstantial heritable componentGenetic contributionProviders
2015
High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort
Liu J, Parajuli S, Blackman E, Gibbs D, Ellis A, Hull A, Beck J, Giri V, Iherjirka P, Khurana J, Ragin C. High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head & Neck 2015, 38: e867-e872. PMID: 25962720, PMCID: PMC4643423, DOI: 10.1002/hed.24117.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaSquamous cell carcinomaAfrican American cohortPolymerase chain reactionAmerican cohortHPV- oropharyngeal squamous cell carcinomaHPV/p16 statusIncidence of HPVAfrican American patientsTumor RegistryCell carcinomaSCC cohortHuman papillomavirusP16 statusAmerican patientsP16 stainingTumor blocksHPVPatientsStandard immunohistochemistryTumor typesP16 negativityCohortChain reactionSurvival
2005
Causes of Preventable Visual Loss in Type 2 Diabetes Mellitus
Hayward R, Cowan C, Giri V, Lawrence M, Makki F. Causes of Preventable Visual Loss in Type 2 Diabetes Mellitus. Journal Of General Internal Medicine 2005, 20: 467-469. PMID: 15963174, PMCID: PMC1490102, DOI: 10.1111/j.1525-1497.2005.40073.x.Peer-Reviewed Original ResearchConceptsAnnual retinal examinationPreventable visual lossLarge referral centerThird of casesPercent of casesRetinal examinationReferral centerVisual lossDiabetic retinopathyMedical recordsWasteful careRetinal photocoagulationType 2PatientsPhotocoagulationSuboptimal timingCurrent performance measuresThirdMellitusRetinopathyVisitsCareMonths